





HOW CRINETICS IS TESTING CRN04777 TO SEE IF IT MIGHT BE A SAFE AND EFFECTIVE MEDICINE FOR CONGENITAL HYPERINSULINISM

Congenital Hyperinsulinism International Family Conference

September 17, 2022




What's going on in
your body and what is
an SST5 receptor?



I'm Pancreas!

insulin

BETA CELL




Genetic mutations in Congenital HI

BETA CELL

↑
Insulin INCREASES


=

↓
Glucose DECREASES
Hypoglycemia





I'm Pancreas!




SST5
receptor

Genetic
mutations
in Congenital HI

BETA CELL






Genetic mutations in Congenital HI


BETA CELL





CRN04777 Activates the SST5 receptor



How drug development works...


PHASE 1
Healthy adults 

PHASE 2
Patient studies 


PHASE 3
More Patient
studies 

Let's Look at What Happened Before and After Treatment in the Phase 1 Study (Healthy Adults)

Insulin





Glucose



—◇— Not Treated (N=6) —●— 30 mg QD (N=6) —●— 60 mg QD (N=6) —●— 120 mg QD (N=5)^(b)



Day 1 measurement occurs prior to the first dose of CRN04777. Measurements on Days 2-9 occurred after ≥ 10 hours overnight fasting and prior to CRN04777 daily dosing. Measurement on Day 10 was after sulfonylurea dose, hence excluded. n=1 subject withdrew consent (not treatment related). QD: Once daily

After One Day of Treatment with CRN04777 Fasting Insulin **Decreased** and Glucose Increased





Day 1 measurement occurs prior to the first dose of CRN04777. Measurements on Days 2-9 occurred after ≥ 10 hours overnight fasting and prior to CRN04777 daily dosing. Measurement on Day 10 was after sulfonylurea dose, hence excluded. n=1 subject withdrew consent (not treatment related). QD: Once daily

What Happened Over Ten Days? Phase 1 Study (Healthy Adults)



Day 1 measurement occurs prior to the first dose of CRN04777. Measurements on Days 2-9 occurred after ≥ 10 hours overnight fasting and prior to CRN04777 daily dosing. Measurement on Day 10 was after sulfonylurea dose, hence excluded. n=1 subject withdrew consent (not treatment related) .QD: Once daily

After 10 Days With Once Daily Oral CRN04777 Phase 1 Study (Healthy Adults)



Day 1 measurement occurs prior to the first dose of CRN04777. Measurements on Days 2-9 occurred after ≥ 10 hours overnight fasting and prior to CRN04777 daily dosing. Measurement on Day 10 was after sulfonylurea dose, hence excluded. n=1 subject withdrew consent (not treatment related) .QD: Once daily

CRN04777 Was Well Tolerated With No Dose Discontinuations Due to Adverse Events

All causality treatment emergent adverse events

Most Frequent TEAEs	Placebo (SAD+MAD) (N=29) n (%)	'4777 (SAD+MAD) (N=78) n (%)
Nausea	0 (0)	15 (19.2)
Vomiting	0 (0)	7 (9.0)
Diarrhoea	0 (0)	5 (6.4)
Headache	0 (0)	5 (6.4)
Chills	0 (0)	3 (3.8)
Hypoglycaemia*	0 (0)	3 (3.8)
Abdominal pain	0 (0)	2 (2.6)
Nasopharyngitis	0 (0)	2 (2.6)
Phlebitis	4 (13.8)	1 (1.3)
Skin Irritation	2 (6.9)	1 (1.3)

*Post glucose clamp and not treatment related

- GI side effects (mild to moderate nausea, vomiting, diarrhea) were the most common treatment-related adverse events, as expected for a somatostatin agonist
 - Time course for these dose-dependent GI events shortly followed treatment initiation and resolved without the need to discontinue study drug
- No study drug discontinuations due to Adverse Events
- No Serious Adverse Events
- No safety signals seen with vital signs, laboratory testing, ECGs

MAD: Multiple-ascending dose; SAD: Single-ascending dose; TEAE: Treatment emergent adverse event; GI: Gastrointestinal; SRL: Somatostatin receptor ligand; ECG: Electrocardiogram

We Are Here!

PHASE **1**
Healthy adults



PHASE 2
Patient studies



PHASE **3**
More Patient studies



**Done with Phase 1
We are getting ready
for Phase 2 studies in
CHI patients**

Stay informed

Visit [Crinetics.com](https://www.crinetics.com)

Stay connected to **CHI**





THANK YOU!



Safe Harbor Statement

This presentation contains forward-looking statements. Crinetics cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential benefits of CRN04777 for patients with congenital or other forms of hyperinsulinism; and plans to advance CRN04777, into additional clinical trials and the timing thereof; plans to meet with regulators and to advance CRN04777 into a clinical program in patients for the treatment of hyperinsulinism; the potential for any of our ongoing clinical trials to show safety or efficacy; the potential of our ongoing discovery efforts to target future indications; and our plans to identify and create new drug candidates for additional diseases. The inclusion of forward-looking statements should not be regarded as a representation by Crinetics that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in Crinetics' business, including, without limitation: preliminary data that we report may change following a more comprehensive review of the data related to the clinical trials and such data may not accurately reflect the complete results of a clinical trial, and the FDA and other regulatory authorities may not agree with our interpretation of such results; advancement of CRN04777 into later stage trials is dependent on and subject to the receipt of further feedback from the FDA; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; the COVID-19 pandemic may disrupt Crinetics' business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity; the company's dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics' clinical trials and nonclinical studies for CRN04777, and its other product candidates; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of the company's product candidates that may limit their development, regulatory approval and/or commercialization; Crinetics may use its capital resources sooner than it expects; and other risks described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Crinetics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and, except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.